Delivery Order SPE2DB22D9102-SPE2DB24FZP81

Award Date 7/15/24
Potential Completion Date 7/16/24
Potential Value $5.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $45,429.60 to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NUCALA 100 MG/ML AUTO-INJECTORML. This order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Nucala 100 mg/ml auto-injectors. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a comprehensive range of pharmaceutical items to fulfill the recurring...
The U.S. Defense Logistics Agency (DLA) has awarded a Firm Fixed Price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,357.40, is for the delivery of NUCALA 100 MG/ML AUTO-INJECTORML. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, to provide a comprehensive range of pharmaceutical items...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NUCALA 100 MG/ML auto-injectors. The contract, valued at $11,357.40, has a period of performance through May 23, 2024. This award is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, which allows the agency to place orders for a wide range of...
The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract worth $3,785.80 to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NUCALA 100 mg/mL auto-injectors. This order is part of a larger indefinite-delivery contract (DLA Contract #4600082013) valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military health facilities worldwide. DMS Pharmaceutical Group...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NUCALA 100 MG/ML auto-injectors. The potential value of this contract is $5,678.70, with a completion date of February 27, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of pharmaceutical products and medical supplies to U.S. government...
The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract worth $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of NUCALA 100 MG/ML auto-injectors. This contract has an ultimate completion date of April 11, 2024 and is not associated with any set-aside program. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract with the Defense Logistics Agency, contract 4600082013 under the SPE2DB program, valued at up...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,929.00, is to provide the NUCALA 100 MG/ML auto-injector to support the recurring medical supply needs of military health facilities. This delivery order is issued under a larger, single-award indefinite delivery contract (IDC) valued at up to $499,999,999 that...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NUCALA 100 MG/ML AUTO-INJECTOR. The delivery order, with a potential value of $1,892.90, has a performance period through December 27, 2023. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles (IDVs) to supply pharmaceuticals and medical...
The U.S. Defense Logistics Agency awarded a $7,571.60 firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the pharmaceutical product NUCALA 100 MG/ML AUTO-INJECTORML. This order was placed under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with the Defense Logistics Agency, which has a total potential value of up to $4,999,999 through 2025. The contract enables the DLA to issue delivery orders for a broad range of...
  • SPE2DB22D9102
    Indefinite Delivery Contract
  • SPE2DB22D9102-SPE2DB24FZP81
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of 4565151275 - NUCALA 100 MG/ML AUTO-INJECTORML. This order was issued under an indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities globally. The IDC, which runs through December 31, 2025, complements DMS Pharmaceutical Group's other prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense sites. This contract award did not utilize any set-aside designations.

Generated 10/14/24, 10:24 AM